The Effect of Glutathione on Development and Prognosis in Non-Muscle-Invasive Bladder Cancer

被引:0
|
作者
Gok, Gamze [1 ]
Kucuk, Tarik [2 ,3 ]
Cimen, Sertac [2 ,3 ]
Gok, Alper [2 ,3 ]
Goktug, Goksel [2 ,3 ]
Erel, Ozcan [1 ]
Imamoglu, Muhammet Abdurrahim [2 ,3 ]
机构
[1] Ankara Bilkent City Hosp, Dept Biochem, TR-06800 Ankara, Turkiye
[2] Univ Hlth Sci, Diskapi Yildirim Beyazit Training & Res Hosp, Fac Med, Dept Urol, TR-06110 Ankara, Turkiye
[3] Etlik City Hosp, Dept Urol, TR-06010 Ankara, Turkiye
关键词
bladder cancer; oxidative stress; glutathione; oxidants/antioxidants; RISK;
D O I
10.3390/jcm13185483
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Glutathione, along with its related enzymes, constitutes a key antioxidant defense mechanism against oxidative stress and cancer formation in the body. Among urological malignancies, bladder cancer ranks second following prostate cancer. Oxidative stress has significant involvement in the development and prognosis of bladder cancer. This investigation aimed to examine the impact of glutathione on prognosis in patients with non-muscle-invasive bladder cancer. Methods: This study included 98 patients with high grade non-muscle-invasive bladder cancer who had undergone intravesical Bacillus Calmette-Gu & eacute;rin therapy and 30 healthy controls with no history of uroepithelial carcinoma of the bladder. The patients with bladder cancer were evaluated in three subgroups. Group 1 consisted of 41 patients who did not experience recurrence during follow-up, Group 2 included 28 patients who had recurrent tumors, and Group 3 consisted of 29 patients who progressed to muscle-invasive stages. Blood samples were collected from all participants. Blood levels of reduced, oxidized, and total glutathione were measured spectrophotometrically. Results: Reduced glutathione levels significantly differed among the groups (p < 0.001), attributed to the control group exhibiting higher reduced glutathione levels compared with Groups 1, 2, and 3 (p < 0.001). There were no significant differences in reduced glutathione levels between Groups 1 and 2, Groups 1 and 3, or Groups 2 and 3 (p > 0.05). Total glutathione levels varied significantly among the groups (p < 0.001), with the control group having higher levels than Groups 1, 2, and 3 (p < 0.001). No significant differences were detected between any of the paired patient groups in terms of total glutathione levels (p > 0.05). Regarding oxidized glutathione levels, the difference was statistically significant (p < 0.001), with the control group showing lower levels than the remaining three groups (p < 0.001). Paired comparisons revealed no significant differences in oxidized glutathione levels (p > 0.05). Conclusions: This study revealed that glutathione had an effect on the emergence of bladder cancer but did not affect its prognosis. Nevertheless, we recommend that future studies with larger bladder cancer patient cohorts should be conducted to comprehensively determine the impact of glutathione on the prognosis of this cancer.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Transurethral Resection of Non-muscle-invasive Bladder Cancer
    Babjuk, Marko
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (07) : 542 - 548
  • [22] Intravesical treatment of non-muscle-invasive bladder cancer
    Bahlburg, Henning
    Noldus, Joachim
    Roghmann, Florian
    UROLOGIE, 2025,
  • [23] Non-muscle-invasive bladder cancer: a vision for the future
    Malmstrom, Per-Uno
    Agrawal, Sachin
    Blackberg, Mats
    Bostrom, Peter J.
    Malavaud, Bernard
    Zaak, Dirk
    Hermann, Gregers G.
    SCANDINAVIAN JOURNAL OF UROLOGY, 2017, 51 (02) : 87 - 94
  • [24] Management of Non-Muscle-Invasive (Superficial) Bladder Cancer
    Nargund, Vinod H.
    Tanabalan, C. K.
    Kabir, M. N.
    SEMINARS IN ONCOLOGY, 2012, 39 (05) : 559 - 572
  • [25] Mutational landscape of non-muscle-invasive bladder cancer
    Hurst, Carolyn D.
    Knowles, Margaret A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (07) : 295 - 303
  • [26] Current management of non-muscle-invasive bladder cancer
    Rodriguez Faba, O.
    Gaya, J. M.
    Lopez, J. M.
    Capell, M.
    De Gracia-Nieto, A. E.
    Gomez Correa, E.
    Breda, A.
    Palou, J.
    MINERVA MEDICA, 2013, 104 (03) : 273 - 286
  • [27] Intravesical chemotherapy in non-muscle-invasive bladder cancer
    Porten, Sima P.
    Leapman, Michael S.
    Greene, Kirsten L.
    INDIAN JOURNAL OF UROLOGY, 2015, 31 (04) : 297 - 303
  • [28] Guideline of guidelines: non-muscle-invasive bladder cancer
    Woldu, Solomon L.
    Bagrodia, Aditya
    Lotan, Yair
    BJU INTERNATIONAL, 2017, 119 (03) : 371 - 380
  • [29] New therapies for non-muscle-invasive bladder cancer
    Chiong, Edmund
    Esuvaranathan, Kesavan
    WORLD JOURNAL OF UROLOGY, 2010, 28 (01) : 71 - 78
  • [30] Predictors of Outcome of Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
    Youssef, Ramy F.
    Lotan, Yair
    THESCIENTIFICWORLDJOURNAL, 2011, 11 : 369 - 381